Drug intelligence / Profile preview

NP003

Development stage: Discontinued
Lead developer: Neuraltus Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

NP003 is an orally bioavailable small-molecule drug candidate originally developed by Neuraltus Pharmaceuticals for the treatment of lysosomal storage disorders, including Fabry disease and Gaucher disease, as well as Parkinson’s disease, although its precise molecular target and mechanism of action have not been publicly detailed.[1][5] It was part of Neuraltus’s early-stage pipeline and received US Qualifying Therapeutic Discovery Project grant support for preclinical development, but development has since been discontinued without progression to late-stage clinical trials.[1][5]

Targets

PAR2 (Protease-activated receptor 2)

Beyond the preview

Go deeper on NP003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP003.

Explore the full profile